- Home
- RMM vs BDTX Comparison
RMM vs BDTX Comparison
Compare RMM & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMM | BDTX |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RMM | BDTX |
|---|---|---|
| Price | $13.56 | $2.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.60 |
| AVG Volume (30 Days) | 66.5K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.96 | 0.38 |
| Revenue | N/A | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.55 | ★ $6.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.32 | $1.20 |
| 52 Week High | $16.10 | $4.94 |
Technical Indicators
Market Signals| Indicator | RMM | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.79 | 34.12 |
| Support Level | $13.63 | $2.52 |
| Resistance Level | $13.74 | $2.69 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 10.38 | 28.77 |
Price Performance
Historical ComparisonAbout RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.